Wells Fargo Upgrades Viridian Therapeutic (VRDN) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush
June 29, 2026 12:25 PM EDTWedbush analyst Laura Chico raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $43.00 (from $32.00) while maintaining a Outperform rating.
The analyst comments "Remain Outperform rated on VRDN, new $43 target. Most notable on the VRDN investor call, management confirmed the Lumvoa price... More
William Blair on Viridian Therapeutic (VRDN): 'We came away from the call incrementally more confident'
June 29, 2026 12:25 PM EDTWilliam Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Viridian Therapeutic (NASDAQ: VRDN)
The analyst comments "On Monday, June 29, Viridian hosted a call to discuss the approval and commercial launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED).... More
